Abstract:【Objective】To investigate the therapeutic effect of Banxia Xiexin Decoction on atrophic gastritis (CAG) by regulating the Toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB) signaling pathway.【Methods】 A total of 104 patients with CAG were randomly divided into two groups, with 52 cases in each. The control group received conventional Western medicine treatment, while the observation group received Banxia Xiexin Decoction in addition to the treatment used in the control group. The two groups were compared in terms of clinical efficacy, traditional Chinese medicine (TCM) symptom scores, immune function indicators, expression levels of the TLR4/NF-κB signaling pathway, inflammatory factors [interleukin-2 (IL-2), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α)], and incidence of adverse reactions.【Results】The total effective rate in the observation group was significantly higher than that in the control group (P<0.05). After treatment, TCM symptom scores in both groups were significantly reduced compared to before treatment (P<0.05), with lower TCM scores observed in the observation group than in the control group (P<0.05). CD3+ and CD4+ levels increased and CD8+ levels decreased in both groups after treatment (P<0.05), with more pronounced improvement in immune function indicators in the observation group (P<0.05). Expression levels of TLR4 mRNA, NF-κB mRNA, and IL-2, IL-6, TNF-α were lower in both groups post-treatment compared to pre-treatment levels, with the observation group showing greater reductions than the control group (P<0.05). The difference in the overall incidence of adverse reactions between the two groups was not statistically significant (P>0.05).【Conclusion】 Banxia Xiexin Decoction in the treatment of CAG patients can significantly improve the clinical effective rate, TCM symptom scores, and immune function indicators. It also effectively alleviates inflammatory responses by regulating the expression of the TLR4/NF-κB signaling pathway, with a high level of safety.